Document Detail


Comparative effects of caffeine and albuterol on the bronchoconstrictor response to exercise in asthmatic athletes.
MedLine Citation:
PMID:  20148372     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The main aim of this study was to evaluate the comparative and additive effects of caffeine and albuterol (short-acting beta (2)-agonist) on the severity of EIB. Ten asthmatic subjects with EIB (exercise-induced bronchoconstriction) participated in a randomized, double-blind, double-dummy crossover study. One hour before an exercise challenge, each subject was given 0, 3, 6, or 9 mg/kg of caffeine or placebo mixed in a flavored sugar drink. Fifteen minutes before the exercise bout, an inhaler containing either albuterol (180 microg) or placebo was administered to each subject. Pulmonary function tests were conducted pre- and post-exercise. Caffeine at a dose of 6 and 9 mg/kg significantly reduced (p<0.05) the mean maximum % fall in post-exercise FEV (1) to -9.0+/-9.2% and -6.8+/-6.5% respectively compared to the double-placebo (-14.3+/-11.1%) and baseline (-18.4+/-7.2%). There was no significant difference (p>0.05) in the post-exercise % fall in FEV (1) between albuterol ( PLUS CAFFEINE PLACEBO) (-4.0+/-5.2%) and the 9 mg/kg dose of caffeine (-6.8+/-6.5%). Interestingly, there was no significant difference (p>0.05) in the post-exercise % fall in FEV (1) between albuterol ( PLUS CAFFEINE PLACEBO) (-4.0+/-5.2%) and albuterol with 3, 6 or 9 mg/kg of caffeine (-4.4+/-3.8, -6.8+/-5.6, -4.4+/-6.0% respectively). Similar changes were observed for the post-exercise % fall in FVC, FEF (25-75%) and PEF. These data indicate that moderate (6 mg/kg) to high doses (9 mg/kg) of caffeine provide a significant protective effect against EIB. It is feasible that the negative effects of daily use of short-acting beta (2)-agonists by asthmatic athletes could be reduced simply by increasing caffeine consumption prior to exercise.
Authors:
T A VanHaitsma; T Mickleborough; J M Stager; D M Koceja; M R Lindley; R Chapman
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial     Date:  2010-02-10
Journal Detail:
Title:  International journal of sports medicine     Volume:  31     ISSN:  1439-3964     ISO Abbreviation:  Int J Sports Med     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-04-26     Completed Date:  2010-08-24     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8008349     Medline TA:  Int J Sports Med     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  231-6     Citation Subset:  IM    
Copyright Information:
Copyright Georg Thieme Verlag KG Stuttgart . New York.
Affiliation:
University of Utah, Exercise and Sports Science, Salt Lake City, United States.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Albuterol / pharmacology,  therapeutic use*
Analysis of Variance
Asthma / drug therapy,  etiology,  physiopathology
Bronchoconstriction / drug effects*
Bronchodilator Agents / pharmacology,  therapeutic use*
Caffeine / pharmacology,  therapeutic use*
Central Nervous System Stimulants / pharmacology,  therapeutic use*
Cross-Over Studies
Double-Blind Method
Drug Synergism
Exercise / physiology*
Exercise Test
Female
Humans
Male
Questionnaires
Respiratory Function Tests
Severity of Illness Index
Sports / physiology
Young Adult
Chemical
Reg. No./Substance:
0/Bronchodilator Agents; 0/Central Nervous System Stimulants; 18559-94-9/Albuterol; 58-08-2/Caffeine
Comments/Corrections
Erratum In:
Int J Sports Med. 2010 Jun;31(6):439

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  ACE and ACTN3 Genes and Muscle Phenotypes in Nonagenarians.
Next Document:  Diurnal and Exercise-Related Variability of Haemoglobin and Reticulocytes in Athletes.